🟢 Cue Biopharma is trading 12% up today — no confirmed catalyst identified

Cue Biopharma is trading at $35.47 (+12.10%), with no new company-specific announcement or confirmed catalyst identified for September 16, 2026.

• Recent developments include the $50 million private placement, CUE-221’s FDA investigational-new-drug submission, and anticipated Phase 2 CSU data.
• Broader equities are higher ahead of the Federal Reserve decision, while biotechnology is lower, leaving the sharp move’s cause unclear.
• Catalyst may require later verification.